Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
GSK walks away from $100M bet on Mersana STING ADC
GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an ADC.
James Waldron
Apr 29, 2026 6:16am
Pfizer cans work on next-gen conjugate in cancer patients
Apr 23, 2026 11:20am
With global goals, Zai Lab offers China reality check
Apr 20, 2026 2:12pm
AACR: Genentech veteran engineers ‘smart’ cancer drug startup
Apr 19, 2026 6:05pm
BioNTech, SynOx plot paths to FDA as tumor trials hit goals
Apr 13, 2026 5:10am
GSK CEO’s ‘scientific courage’ propels ADC toward ph. 3 tests
Apr 12, 2026 10:10am
